EasySep™小鼠TIL（CD45）正选试剂盒
关于我们
-
The 21st Annual STEMCELL Science Fair Fun Run Registration is Now Open! The STEMCELL Science Fair Fun Run is the largest timed 5K race in BC and one of the largest events in BC's technology industry -
NGen Funding to Transform Manufacturing of Critical Materials in Gene Therapies NGen has approved Supercluster funding for a transformative $4.2 million project led by iVexSol Canada to develop an advanced manufacturing process for lentiviral vectors -
STEMCELL Technologies Wins Deloitte Best Managed Companies Award STEMCELL Technologies is proud to announce that the company has been selected as a winner of Canada's Best Managed Companies program for 2019 -
STEMCELL Technologies Launches mTeSR™ Plus, a Next-Generation Culture System for Human ES and iPS Cell Maintenance The new medium has undergone successful beta testing with several members of the Stem Cell COREdinates group and has completed rigorous in-house validation testing -
STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339 -
The Science Fair Foundation of BC Announces STEMCELL Technologies as New Title Sponsor of the Fun Run The Science Fair Foundation of BC is excited to welcome STEMCELL Technologies as the new title sponsor of The STEMCELL Science Fair Fun Run -
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System STEMCELL Technologies has today announced that they have signed an exclusive license agreement with Brigham and Women's Hospital for rights to commercialize technologies for the generation of human pluripotent stem cell-derived kidney organoids -
STEMCELL Technologies Announces $45 Million Government Funding for Advanced Manufacturing Facility The funding agreement will accelerate the Vancouver company's rapidly scaling business of providing cutting-edge reagents and tools to support life science researchers around the world working in the cell therapy and regenerative medicine fields
